Segelov, E., Waring, P., Desai, J., Wilson, K., Gebski, V., Thavaneswaran, S., . . . Shapiro, J. (2016). ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer.
Citação norma ChicagoSegelov, Eva, et al. "ICECREAM: Randomised Phase II Study of Cetuximab Alone or in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer With Either KRAS, NRAS, BRAF and PI3KCA Wild Type, or G13D Mutated Tumours." BMC Cancer 2016.
ציטוט MLASegelov, Eva, et al. "ICECREAM: Randomised Phase II Study of Cetuximab Alone or in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer With Either KRAS, NRAS, BRAF and PI3KCA Wild Type, or G13D Mutated Tumours." BMC Cancer 2016.